These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34129329)

  • 1. Discovery and Optimization of a Novel 2
    Wei Y; Tang Y; Zhou Y; Yang Y; Cui Y; Wang X; Wang Y; Liu Y; Liu N; Wang Q; Li C; Ruan H; Zhou H; Wei M; Yang G; Yang C
    J Med Chem; 2021 Jul; 64(13):9078-9099. PubMed ID: 34129329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
    Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
    Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
    Yamani A; Zdżalik-Bielecka D; Lipner J; Stańczak A; Piórkowska N; Stańczak PS; Olejkowska P; Hucz-Kalitowska J; Magdycz M; Dzwonek K; Dubiel K; Lamparska-Przybysz M; Popiel D; Pieczykolan J; Wieczorek M
    Eur J Med Chem; 2021 Jan; 210():112990. PubMed ID: 33199155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
    Wu L; Zhang C; He C; Qian D; Lu L; Sun Y; Xu M; Zhuo J; Liu PCC; Klabe R; Wynn R; Covington M; Gallagher K; Leffet L; Bowman K; Diamond S; Koblish H; Zhang Y; Soloviev M; Hollis G; Burn TC; Scherle P; Yeleswaram S; Huber R; Yao W
    J Med Chem; 2021 Aug; 64(15):10666-10679. PubMed ID: 34269576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
    Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
    PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and evaluation of a pyrazolo[3,4-d]pyrimidine derivative as a novel and potent TGFβ1R1 inhibitor.
    Wang Y; Liu Y; Zhang Y; Zhang Z; Xu L; Wang J; Yang Y; Hu B; Yao Y; Wei M; Wang J; Tang B; Zhang K; Liu S; Yang G
    Eur J Med Chem; 2024 May; 271():116395. PubMed ID: 38626523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors.
    Wang Y; Pan Y; Lv Z; Gou S
    Eur J Med Chem; 2024 May; 271():116415. PubMed ID: 38643670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors.
    Ran K; Zeng J; Wan G; He X; Feng Z; Xiang W; Wei W; Hu X; Wang N; Liu Z; Yu L
    Eur J Med Chem; 2021 Aug; 220():113499. PubMed ID: 33940465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z
    J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
    Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.
    Zhang Y; Lv H; Luo L; Xu Y; Pan Y; Wang Y; Lin H; Xiong J; Guo P; Zhang J; Li X; Ye F
    Eur J Med Chem; 2018 Sep; 157():1300-1325. PubMed ID: 30195240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.
    Wang Y; Li L; Fan J; Dai Y; Jiang A; Geng M; Ai J; Duan W
    J Med Chem; 2018 Oct; 61(20):9085-9104. PubMed ID: 29522671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
    Zhang CH; Chen K; Jiao Y; Li LL; Li YP; Zhang RJ; Zheng MW; Zhong L; Huang SZ; Song CL; Lin WT; Yang J; Xiang R; Peng B; Han JH; Lu GW; Wei YQ; Yang SY
    J Med Chem; 2016 Nov; 59(21):9788-9805. PubMed ID: 27739679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
    Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
    Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models.
    Peng X; Hou P; Chen Y; Dai Y; Ji Y; Shen Y; Su Y; Liu B; Wang Y; Sun D; Jiang Y; Zha C; Xie Z; Ding J; Geng M; Ai J
    J Exp Clin Cancer Res; 2019 Aug; 38(1):372. PubMed ID: 31438996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.